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Abstract
As the field of survivorship research grows, the need for translation is imperative to expand new 
knowledge into arenas that directly impact survivors. This commentary seeks to encourage 
research focused on dissemination and translation of survivorship interventions and programs, 
including practice-based research. We overview diffusion, dissemination and translation in the 
context of cancer survivorship and present the RE-AIM and Knowledge to Action frameworks as 
approaches that can be used to expand research into communities. Many academic, governmental, 
and community-based organizations focus on cancer survivor. Future survivorship research should 
contribute to harmonizing these assets to identify effective interventions, maximize their reach and 
adoption, and integrate promising practices into routine care.
Background
The field of cancer survivorship has steadily progressed from gaining recognition as a 
distinct phase of the cancer experience toward achieving a better understanding of the 
multifaceted challenges associated with cancer and its treatment. Cancer survivorship 
research has elucidated late and long-term impacts of cancer and has led to interventions and 
changes in practice intended to improve quality of life and health outcomes of cancer 
survivors. For example, survivorship researchers and pediatric oncologists collaboratively 
developed the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines to 
inform the screening, surveillance, and management of adverse effects related to childhood 
cancers (1). Another example is the recent publication of 2 studies related to breast cancer. 
One study showed that arm resistance exercise did not increase lymphedema and another 
showed that early-stage cancer axillary lymph node dissection did not offer survival benefits 
over sentinel lymph node dissection (2, 3). These new findings have the potential to 
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significantly alter the prevalence of lymphedema, a dreaded sequlae of breast cancer, as well 
as debunk misconceptions about how it is affected by exercise. Research has also shown the 
impact of psychosocial, informational, and behavioral interventions on cancer survivors (4–
8).
Although this progress has been promising, advances in cancer survivorship need to be 
replicated and translated into community settings where 85% of cancer patients are treated 
(9). Replicating interventions will move the science forward by confirming that benefits 
persist in real-world settings. This is particularly true for communities with poor health care 
access or which serve patients who have a limited understanding of cancer and its potential 
consequences. Therefore, the next important step in the progression of survivorship research 
is to investigate how to best disseminate and translate emerging evidence. Dissemination 
research focuses on effective methods to influence target groups to receive, accept, and use 
information and interventions (10). Translation is the process of ensuring effective and 
widespread use of science-based programs, practices, and policies (11). Dissemination and 
translation are of utmost importance because they extend the value of original research by 
connecting findings into actions and programs that impact individuals on a larger scale.
The goal of this article is to encourage the conduct of more relevant practice-based research 
that can inform and improve care of survivors. After reviewing survivorship research in the 
context of diffusion, dissemination, and translation, we introduce 2 practical frameworks, 
RE-AIM and Knowledge to Action (K2A), to support the “uptake” of research by 
practitioners (11, 12). Finally, we describe challenges, opportunities, and suggested future 
directions for the dissemination and translation of survivorship research.
Survivorship Research in the Context of Diffusion, Dissemination, and 
Translation
Dissemination is a complex process that goes far beyond the publication of results. 
Traditionally, clinical and social scientists focus on testing the value of interventions in 
carefully chosen and controlled environments (efficacy). Once completed, however, there are 
often limited expectations and support for testing the effect of the interventions in everyday 
practice (effectiveness). A reason for this disconnect is that the theory, skills, and experience 
required to disseminate evidence-based practices are distinct from those needed to develop 
and test novel interventions. The terms diffusion, dissemination, and translation are all 
relevant to this process, but each term has a unique meaning (13).
Diffusion
Diffusion theory is largely based on the work of Everett Rodgers, a rural sociologist who 
identified elements that influence the spread of a new idea and described factors that 
ultimately influence its adoption or rejection (14). These factors include the relative 
advantage of the innovation over the status quo, its compatibility into one’s current life or 
work flow, the perception of how simple or complex it would be to adopt, the feasibility of 
testing the innovation before it is fully adopted, and the visibility of the change to other 
observers (14). Diffusion theory relates to the current state of cancer survivorship research 
Pollack et al. Page 2
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 June 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
because the premise of preventing and addressing the late and long-term effects of cancer 
and cancer treatment is a relatively new idea in the medical care model. Furthermore, the 
adoption of survivorship interventions requires cancer survivors and/or their providers to 
change current practices.
Dissemination
In contrast to the passive, uncontrolled spread of diffusion, dissemination implies a more 
strategic approach to encouraging the adoption of new ideas and practices (15). In 
dissemination science, the focus shifts from change occurring due to the attributes of an 
innovation itself, to a more active, deliberate strategy for encouraging change in a targeted 
group. Considerations for dissemination of interventions include social context, resources, 
leadership, timing, and preferred channel of delivery (13). In some ways, principles of 
dissemination mirror those used in marketing, as they focus on preferred information 
channels of potential adopters, refining interventions through pretesting research, and 
supporting decisions to adopt and maintain change through trials, support, and technical 
assistance (16). Using the earlier example of COG guidelines, companion patient education 
materials, Health Links, were developed and made freely available online as a potential 
dissemination tool (17).
Translation
As a concept, translation covers the spectrum from basic discovery to developing 
interventions, developing guidelines, changing practice through diffusion and dissemination, 
and evaluating outcomes of changed practices (18–20). Translation research emerged to 
address the gap between discovery science and effective practice because many innovations 
developed through academic research do not reach practitioners, and if they do, adoption is 
often sporadic and slow (21–23). Translation maintains a strong focus within basic science 
and is concerned with all aspects of research on testing interventions for acceptability and 
adoption into practice (24). Much of the survivorship research has focused on determining 
efficacy of interventions. A next step is to expand cancer survivorship research to address 
translational issues concerning whether and how research findings relate to practice (25). 
Table 1 highlights some of the differences between what is valued in research versus 
practice.
To illustrate diffusion, dissemination, and translation of a survivorship intervention, consider 
survivorship care planning, a major recommendation of a 2005 Institute of Medicine (IOM) 
Report, From Cancer Patient to Cancer Survivor: Lost in Transition (26). A cancer 
survivorship care plan is a written summary of critical information needed for a survivor’s 
long-term care, including cancer type, treatments received, potential late effects of the 
cancer or treatments, recommendations for medical follow-up, and information related to 
health promotion and psychosocial resources (26–28). Care plans are seen as valuable for 
educating survivors and their caregivers about their cancer care and future health concerns, 
as well as facilitating coordination between oncology, primary care, and available support 
services (29). Within the context of diffusion and factors that lead to adoption of a new 
practice, survivorship care plans may be seen as having advantages over current practice by 
providing the survivor and primary care provider with better information on the diagnosis, 
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treatment, and potential consequences of cancer (30). However, the oncology practitioner, 
who likely would be responsible for creating survivorship care plans for each patient, may 
view it as a complex, time-consuming process that does not easily fit into workflow and has 
not yet been proven effective or useful (29). With regard to dissemination, professional 
societies such as the American Society of Clinical Oncology and the Oncology Nursing 
Society actively encourage the use of survivorship care plans through educating providers on 
their objectives and core elements and providing templates to ease integration into practice. 
If dissemination is successful, there will still be a need for translation as best practices in 
survivorship care planning may differ by practice setting, recipient’s health literacy, and 
intended use of the document (30).
Frameworks for Research Translation: RE-AIM and Knowledge to Action
Two frameworks that researchers and organizations should consider for translating research 
into practice within communities are RE-AIM and K2A (11, 12).
RE-AIM provides a framework for effectively implementing science into “real-world” 
settings (12, 31, 32). It provides a comprehensive approach to research translation by 
identifying 5 components essential for creating and evaluating effective, generalizable, and 
sustainable interventions (31, 32). These components are (i) Reach: the number of people 
impacted by the intervention, including those most in need; (ii) Efficacy/effectiveness: the 
intervention’s impact on quality of life and outcomes, including those which are negative or 
unintended; (iii) Adoption: the number of institutions willing and able to implement the 
program; (iv) Implementation: the quantity and quality of delivering intervention 
components; and (v) Maintenance: the extent in which the intervention becomes routine 
practice at the institutional level, and the measurement of long-term effects on health 
outcomes at the individual/population level (12, 31–33). RE-AIM’s multilevel design allows 
programmatic intervention at both the participant (Reach, Effectiveness, and Maintenance) 
and institutional (Adoption, Implementation, and Maintenance) level (12, 31, 32). The 
framework also addresses both internal (Efficacy and Implementation) and external (Reach 
and Adoption) validity (33). RE-AIM is particularly relevant to the translation and 
dissemination of cancer survivorship research because as a relatively new field, this tool 
provides a systematic, standardized approach to applying the research.
The K2A framework outlines several high-level processes necessary to translate chronic 
disease research. The K2A schematic identifies 3 phases: (i) Research: testing of 
interventions to determine effectiveness and appropriateness for translation; (ii) Translation: 
developing actionable resources and supporting structures for implementing interventions; 
and (iii) Institutionalization: maintaining the intervention as an established activity (11). Key 
features of the K2A framework include recognizing that intentional decisions are needed to 
translate research and adopt interventions, relationships between the practice communities 
and researchers are inherent to successful translation, and evaluation underpins the entire 
translation process (11).
Pollack et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 June 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Challenges and Opportunities
The components of these frameworks highlight challenges to bridging the divide between 
survivorship research and practice. Reach identifies the challenge of defining a community 
to target for translation, which for survivorship can mean many different groups such as 
cancer survivors, their family members, clinical providers, and organizations focused on 
survivors. Reach should also address the sparse representation of minority and economically 
disadvantaged participants because survivorship research in diverse cultural settings is 
limited (34). In addition, for all populations, it is important for researchers to report both 
uptake and attrition in studies, to allow potential users to assess the generalizability of 
reported findings. Organizations that provide care to survivors may not share the same 
features as the original research setting. Because the adolescence of the field of survivorship, 
the evidence base for effectiveness of interventions and programs is small. Thus, research 
that specifically addresses translation, as discussed in the K2A continuum, is warranted 
because individual communities may require different approaches to foster change due to 
their unique composition, beliefs, and experience. Translation needs to address how a 
community makes health decisions as well as its broader cultural, economical, historical, 
and political context (35). Adoption and implementation of an intervention or new practice 
often depends on its feasibility and community readiness (36). Context and adaptability of 
innovations become very important for scientific knowledge to be translated into practice 
and policy. To be maintained and to achieve institutionalization, survivorship science must 
shift toward and achieve both internal and external validity (23).
In response, there is growing consensus to incorporate both practice-based and research-
based evidence in evaluating the best approach when choosing among interventions. Green 
and colleagues concluded that health science research would improve its influence on policy, 
professional practice, and public impact if the research questions ask “How can we make 
science more practice-based?” rather than “How can we make practice more science-based?” 
(23). To do so, the health research agenda should be determined by the needs of patients and 
populations through researcher–practitioner collaborations with resource allocation 
proportionate to the magnitude of the task (23, 37).
Dissemination and translation research should be a 2-way street. There are many 
survivorship interventions and programs that are being widely used, but have not been 
evaluated. The development, dissemination, and adoption of such materials and activities 
often precede research because they seem to meet the needs of the community. These 
programs and the lessons learned from their evolution should inform the survivorship 
research agenda. An advantage to doing so is that materials developed with and for a 
targeted survivorship community may possess an inherent sociocultural context that will 
ultimately influence its feasibility and acceptance.
How do we track progress in translation? Measuring outcomes is critical for decisions about 
adopting or continuing interventions and common measurements are necessary for 
evaluating comparative effectiveness. There is a definite need to use and further develop 
methodology related to disseminating efficacious survivorship interventions. Recognizing 
that public health practice is an ideal environment to better understand and address 
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challenges related to external validity, one method to consider is community-based 
participatory research. Community-based participatory research is a collaborative process 
that seeks input and engagement of the targeted community in the development of research 
questions, data collection, intervention development, and evaluation (38). Another approach 
to inform the feasibility of survivorship interventions is economic research because to 
encourage adoption, interventions will ideally have high reach at low cost (13). Our earlier 
example of survivorship care planning shows this need because the cost of preparing and 
delivering care plans is currently not covered by most medical insurers. In response, several 
community hospitals in Colorado are using patient navigators to promote and deliver 
survivorship care plans; and this has provided an opportunity to evaluate the feasibility and 
comparative costs of alternative dissemination routes for care planning (B.C. Risendal; 
personal communication). Finally, a non-traditional but potentially relevant approach to 
dissemination and measurement of survivorship interventions is continuous quality 
improvement (CQI). Through continually identifying, measuring, and attempting to improve 
processes toward a stated outcome, CQI can identify expectations and be responsive to the 
unique needs of a targeted community (39). The application of any of these methods would 
contribute greatly to the field of survivorship.
Future Directions
As we strive toward the goal of delivering evidence-based, coordinated cancer care and 
empowering survivors to lead healthy lives, we should consider the many assets currently 
available. Nonprofit organizations serving survivors; comprehensive cancer control 
coalitions within each state, tribe, and territory; and influential individuals within targeted 
communities can all be enthusiastic allies in dissemination with attention toward 
sustainability (40, 41). Figure 1 illustrates key partners who are vital to the advancement of 
cancer survivorship. Future work in survivorship needs to focus on weaving these assets 
together. One such example is 2 CDC-supported pilot projects being conducted at academic 
and community cancer clinics to determine the feasibility and impact of implementing 
survivorship care plans developed by a collaboration of nonprofit and private organizations 
and based on IOM guidance (26, 28, 42). A second asset is the growing amount of research 
and number of researchers focused on treatment improvements, rehabilitation, late effects, 
and psychosocial support related to cancer survivorship. These resources make now an ideal 
time to embrace dissemination and translation research and begin to address the challenges 
of integrating research and practice. Researchers and program planners should use available 
resources and tools to increase translation. For example, Cancer Control P.L.A.N.E.T. 
(planning, implementation, and evaluation of evidence-based cancer control interventions) is 
a website designed for public health planners to access cancer control resources such as 
evidence-based interventions and programs and for researchers to locate programmatic 
partners (43). Current research networks and funding mechanisms for the dissemination and 
translation of cancer survivorship interventions include the Agency for Healthcare Research 
and Quality’s ACTION Network, the Prevention Research Centers program within Centers 
for Disease Control and Prevention, and National Cancer Institute’s Designing for 
Dissemination initiative (44–46). If investigators are encouraged to report their work in the 
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RE-AIM framework (12), program planners may be better equipped to decide which 
survivorship interventions work best in their community.
In conclusion, timely and effective translation of research to public health practice is 
paramount in supporting the nearly 12 million cancer survivors currently living in the United 
States (47). This overview highlights many theoretical and practical approaches to making 
research and interventions more relevant at the community level. As our depth in knowledge 
about cancer survivorship grows, it should be equally broad. A shift toward increasing 
research on dissemination and involving targeted communities in the development of 
research questions and the translation of results could have an enormous impact on ensuring 
the relevance and adoption of survivorship interventions.
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Figure 1. 
Key partners in the dissemination and translation of cancer survivorship research.
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Table 1
Comparison of factors valued in research versus practice
Research Practice
Theoretical framework Cost
Funding available Reach
Previous research Relative advantage
Study design Uptake
Methodology Policy support
Inclusion/exclusion criteria Culture
Isolation of key variables  Organizational
Validity  Targeted population
Controlled setting Feasibility
Defined outcome Adaptability
Fidelity Practicality
Reproducibility Personnel
Internal validity Simplicity
Reporting of selected results Sustainability
Efficacy Communication
Trust
External validity
Effectiveness
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